Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Impact of Oral Antibiotic Treatment on C. Difficile
- Conditions
- Interventions
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Duke University
- Target Recruit Count
- 33
- Registration Number
- NCT02057198
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2020-07-31
- Target Recruit Count
- 27
- Registration Number
- NCT02037295
- Locations
- 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States
Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin
- Conditions
- Interventions
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- University of Tennessee
- Target Recruit Count
- 430
- Registration Number
- NCT02027532
- Locations
- 🇺🇸
Erlanger Health System, Chattanooga, Tennessee, United States
Regional Prophylactic Vancomycin in Revision Total Knee Replacement
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT02020031
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Actelion
- Target Recruit Count
- 632
- Registration Number
- NCT01987895
- Locations
- 🇪🇸
Investigator Site, Majadahonda, Spain
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 850
- Registration Number
- NCT01984684
- Locations
- 🇨🇳
Melinta 303 Study Site, Zhonghe, Taiwan
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Actelion
- Target Recruit Count
- 631
- Registration Number
- NCT01983683
- Locations
- 🇭🇷
Investigator Site 2784, Zagreb, Croatia
🇭🇷Investigator Site 2786, Zagreb, Croatia
🇭🇷Investigator Site 2780, Zagreb, Croatia
Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT01975662
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Effect of Probiotic Supplementation on Endothelial Function
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 21
- Registration Number
- NCT01952834
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwauke, Wisconsin, United States
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
- Conditions
- Interventions
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 30
- Registration Number
- NCT01942447
- Locations
- 🇩🇪
Universitaetsklinikum Tuebingen, Tuebingen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.